關(guān)鍵詞

Divarasib 匹伐他汀 尼塞韋單抗?呼吸道合胞病毒 米吉珠單抗 度普利尤單抗 托珠單抗 依若奇單抗 替瑞利尤單抗 阿替利珠單抗

?

#今日行業(yè)熱點#

①The New England Journal of Medicine：Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

臨床試驗：選擇性KRAS G12C抑制劑Divarasib在KRAS G12C突變實體腫瘤中的作用

DOI: 10.1056/NEJMoa2303810

②The New England Journal of Medicine：Pitavastatin to Prevent Cardiovascular Disease in HIV Infection

臨床試驗：匹伐他?。≒itavastatin）預(yù)防在人類免疫缺陷病毒(HIV)感染者心血管疾病的Ⅲ期試驗

DOI: 10.1056/NEJMoa2304146

③Morbidity and Mortality Weekly Report (MMWR)：Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study

美國CDC免疫實踐咨詢委員會：使用尼塞韋單抗（Nirsevimab）預(yù)防嬰幼兒呼吸道合胞病毒疾病

DOI: 10.15585/mmwr.mm7234a4

④Science Translational Medicine：FcγRIIB expressed on CD8+ T cells limits responsiveness to PD-1 checkpoint inhibition in cancer

CD8+ T細(xì)胞表達(dá)的抑制性受體FcγRIIB限制了腫瘤對PD-1檢查點抑制的反應(yīng)性

DOI: 10.1126/scitranslmed.add1868

⑤Clinical Pharmacokinetics：Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies

臨床分析：靶向IL-23亞基的單克隆抗體米吉珠單抗（Mirikizumab）在中度至重度活動性潰瘍性結(jié)腸炎患者中的藥代動力學(xué)特征

DOI: 10.1007/s40262-023-01281-z

⑥D(zhuǎn)rugs and Aging：Efficacy and Safety of Dupilumab in Older Patients (Aged 80 Years and Above) with Atopic Dermatitis: A Prospective Study

臨床研究：度普利尤單抗（Dupilumab）用于80歲及以上老年特應(yīng)性皮炎患者的療效和安全性:一項前瞻性研究

DOI: 10.1007/s40266-023-01059-9

⑦抗IL-6R重組人源化單抗托珠單抗（Tocilizumab）單藥用于成人中度至重度活動性類風(fēng)濕關(guān)節(jié)炎（RA）的新適應(yīng)癥獲中國國家藥監(jiān)局（NMPA）上市批準(zhǔn)

⑧靶向于IL-12/IL-23的全人源單克隆抗體依若奇單抗上市申請已經(jīng)獲CDE受理，用于中度至重度斑塊型銀屑病Ⅲ

⑨TIGIT抗體替瑞利尤單抗（tiragolumab）聯(lián)合PD-L1抑制劑阿替利珠單抗（atezolizumab）用于PD-L1高表達(dá)的局部晚期或轉(zhuǎn)移性非小細(xì)胞肺癌的Ⅲ期試驗SKYSCRAPER-01最新結(jié)果積極

⑩重組帶狀皰疹疫苗Shingrix在中國開展的首個保護(hù)效力研究取得積極結(jié)果

科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！